These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16503948)

  • 1. Should future health-care costs be discounted? The case of diabetes in Australia.
    Scuffham PA
    Intern Med J; 2006 Mar; 36(3):148-9. PubMed ID: 16503948
    [No Abstract]   [Full Text] [Related]  

  • 2. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study.
    Davis WA; Knuiman MW; Hendrie D; Davis TM
    Intern Med J; 2006 Mar; 36(3):155-61. PubMed ID: 16503950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of type 2 diabetes prevention.
    Kissimova-Skarbek K
    Przegl Lek; 2006; 63 Suppl 4():9-11. PubMed ID: 16967708
    [No Abstract]   [Full Text] [Related]  

  • 4. State of diabetes care in the United States.
    Blonde L
    Am J Manag Care; 2007 Apr; 13 Suppl 2():S36-40. PubMed ID: 17417931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New, expensive antidiabetics for the treatment of type-2 diabetes--pro].
    Müller-Wieland D
    Dtsch Med Wochenschr; 2010 May; 135(18):922. PubMed ID: 20425678
    [No Abstract]   [Full Text] [Related]  

  • 6. [Obesity and diabetes mellitus: increasing problems call for increasing efforts].
    Nauck M
    Dtsch Med Wochenschr; 2010 May; 135(18):901. PubMed ID: 20425673
    [No Abstract]   [Full Text] [Related]  

  • 7. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery.
    Makary MA; Clark JM; Shore AD; Magnuson TH; Richards T; Bass EB; Dominici F; Weiner JP; Wu AW; Segal JB
    Arch Surg; 2010 Aug; 145(8):726-31. PubMed ID: 20713923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [By the year 2030 some 40% of the German population could be Type 2 diabetics--the big bang in the public health system].
    Fuessl HS
    MMW Fortschr Med; 2006 May; 148(21):27. PubMed ID: 16796184
    [No Abstract]   [Full Text] [Related]  

  • 9. Estimating the direct cost of Type 2 diabetes in Greece: the effects of blood glucose regulation on patient cost.
    Athanasakis K; Ollandezos M; Angeli A; Gregoriou A; Geitona M; Kyriopoulos J
    Diabet Med; 2010 Jun; 27(6):679-84. PubMed ID: 20546287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation today for practice tomorrow].
    Klein H
    Dtsch Med Wochenschr; 2013 May; 138(18):933. PubMed ID: 23613370
    [No Abstract]   [Full Text] [Related]  

  • 11. Richard Milne responds to PHARMAC on discounting future health benefits and costs.
    Milne R
    N Z Med J; 2005 Aug; 118(1220):U1620. PubMed ID: 16132078
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The German diabetes dilemma: DMP: insufficient management of the diabetic patient in general practice?].
    MMW Fortschr Med; 2005 Oct; 147(41):10. PubMed ID: 16270503
    [No Abstract]   [Full Text] [Related]  

  • 14. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB
    Gesundheitswesen; 2006 Oct; 68(10):600-12. PubMed ID: 17099820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention and early therapy play too minor a role in our health care system].
    Rothe HJ
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():22-3. PubMed ID: 14694840
    [No Abstract]   [Full Text] [Related]  

  • 16. ["The Lantus Case": What is the benefit of health economics?].
    Schöffski O
    Dtsch Med Wochenschr; 2010 May; 135(20):1033-5. PubMed ID: 20461663
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment.
    Walson PD; Mullins CD; Lyles A; West JA
    Clin Ther; 2008 Oct; 30(10):1889. PubMed ID: 19014844
    [No Abstract]   [Full Text] [Related]  

  • 18. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial.
    Janka HU; Högy B
    Eur J Health Econ; 2008 May; 9(2):165-70. PubMed ID: 17530309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.